Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Neuprex rBPI-21 bactericidal/permeability increasing protein: Began a Phase II efficacy trial in 400 patients who have received at least two units of blood with

The study will enroll patients whose onset of trauma

Read the full 90 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE